• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Mutation profile and its correlation with clinicopathology in Chinese hepatocellular carcinoma patients.中国肝细胞癌患者的突变谱及其与临床病理学的相关性
Hepatobiliary Surg Nutr. 2021 Apr;10(2):172-179. doi: 10.21037/hbsn.2019.09.17.
2
or mutations are associated with higher tumor mutational burden and worse survival in hepatocellular carcinoma.OR突变与肝细胞癌中更高的肿瘤突变负担和更差的生存率相关。
J Cancer. 2021 Jan 1;12(1):217-223. doi: 10.7150/jca.48983. eCollection 2021.
3
Integrative analysis of aberrant Wnt signaling in hepatitis B virus-related hepatocellular carcinoma.乙型肝炎病毒相关肝细胞癌中异常Wnt信号通路的综合分析
World J Gastroenterol. 2015 May 28;21(20):6317-28. doi: 10.3748/wjg.v21.i20.6317.
4
Mutations Were Associated with the Early Recurrence of Patients with HCC Underwent Hepatectomy.突变与接受肝切除术的肝癌患者早期复发相关。
Pharmgenomics Pers Med. 2021 Feb 16;14:269-278. doi: 10.2147/PGPM.S294307. eCollection 2021.
5
Genomic profiling of combined hepatocellular-cholangiocarcinoma reveals similar genetics to hepatocellular carcinoma.联合型肝细胞癌-胆管细胞癌的基因组分析揭示其与肝细胞癌具有相似的遗传学特征。
J Pathol. 2019 Jun;248(2):164-178. doi: 10.1002/path.5243. Epub 2019 Mar 8.
6
Comprehensive analyses of mutations and hepatitis B virus integration in hepatocellular carcinoma with clinicopathological features.肝细胞癌中具有临床病理特征的突变和乙型肝炎病毒整合的综合分析。
J Gastroenterol. 2016 May;51(5):473-86. doi: 10.1007/s00535-015-1126-4. Epub 2015 Nov 9.
7
Implications of driver genes associated with a high tumor mutation burden identified using next-generation sequencing on immunotherapy in hepatocellular carcinoma.利用下一代测序技术鉴定出的与高肿瘤突变负担相关的驱动基因对肝细胞癌免疫治疗的影响
Oncol Lett. 2020 Apr;19(4):2739-2748. doi: 10.3892/ol.2020.11372. Epub 2020 Feb 5.
8
Histological subtypes of hepatocellular carcinoma are related to gene mutations and molecular tumour classification.肝细胞癌的组织学亚型与基因突变和分子肿瘤分类有关。
J Hepatol. 2017 Oct;67(4):727-738. doi: 10.1016/j.jhep.2017.05.014. Epub 2017 May 19.
9
Integrated exome sequencing and microarray analyses detected genetic defects and underlying pathways of hepatocellular carcinoma.整合外显子组测序和微阵列分析检测了肝细胞癌的遗传缺陷和潜在途径。
Cancer Genet. 2023 Aug;276-277:30-35. doi: 10.1016/j.cancergen.2023.06.002. Epub 2023 Jun 28.
10
A systematic analysis with the hierarchical cluster analysis strategy on the complex interaction of TERT and CTNNB1 somatic mutations in Vietnamese hepatocellular carcinoma patients.越南肝细胞癌患者 TERT 和 CTNNB1 体细胞突变复杂相互作用的系统分析及层次聚类分析策略。
Gene. 2024 Nov 15;927:148646. doi: 10.1016/j.gene.2024.148646. Epub 2024 Jun 6.

引用本文的文献

1
Splenectomy and risk of hepatocellular carcinoma.脾切除术与肝细胞癌风险
World J Hepatol. 2025 Jul 27;17(7):107603. doi: 10.4254/wjh.v17.i7.107603.
2
Consensus artificial intelligence-driven prognostic signature for predicting the prognosis of hepatocellular carcinoma: a multi-center and large-scale study.用于预测肝细胞癌预后的人工智能驱动的共识预后特征:一项多中心大规模研究
NPJ Precis Oncol. 2025 Jul 1;9(1):207. doi: 10.1038/s41698-025-01010-8.
3
Preoperative plasma cell-free DNA chromosomal instability predicts microvascular invasion in hepatocellular carcinoma: a prospective study.术前血浆游离DNA染色体不稳定预测肝细胞癌微血管侵犯:一项前瞻性研究
BMC Cancer. 2025 May 13;25(1):867. doi: 10.1186/s12885-025-14268-9.
4
Migrasome-related ITGA5 for predicting prognosis, immune infiltration and drug sensitivity of hepatocellular carcinoma.与迁移小体相关的整合素α5用于预测肝细胞癌的预后、免疫浸润和药物敏感性
Apoptosis. 2025 Mar 27. doi: 10.1007/s10495-025-02103-2.
5
Genetic alterations are related to clinicopathological features and risk of recurrence/metastasis of hepatocellular carcinoma.基因改变与肝细胞癌的临床病理特征及复发/转移风险相关。
Eur J Cancer Prev. 2025 Sep 1;34(5):456-466. doi: 10.1097/CEJ.0000000000000939. Epub 2024 Nov 27.
6
Tumor immune microenvironment analysis of non-small cell lung cancer development through multiplex immunofluorescence.通过多重免疫荧光对非小细胞肺癌发展进行肿瘤免疫微环境分析。
Transl Lung Cancer Res. 2024 Sep 30;13(9):2395-2410. doi: 10.21037/tlcr-24-379. Epub 2024 Sep 20.
7
Exploring the Impact of the β-Catenin Mutations in Hepatocellular Carcinoma: An In-Depth Review.探讨β-连环蛋白突变在肝细胞癌中的作用:深入综述。
Cancer Control. 2024 Jan-Dec;31:10732748241293680. doi: 10.1177/10732748241293680.
8
High Tumor Mutational Burden in Hepatocellular Carcinoma.肝细胞癌中的高肿瘤突变负荷
Cureus. 2024 Aug 29;16(8):e68132. doi: 10.7759/cureus.68132. eCollection 2024 Aug.
9
Identification and Validation of a Novel Tertiary Lymphoid Structures-Related Prognostic Gene Signature in Hepatocellular Carcinoma.肝细胞癌中一种新型三级淋巴结构相关预后基因特征的鉴定与验证
World J Oncol. 2024 Aug;15(4):695-710. doi: 10.14740/wjon1893. Epub 2024 Jul 5.
10
Novel genetic alterations in liver cancer distinguish distinct clinical outcomes and combination immunotherapy responses.肝癌中的新型基因改变可区分不同的临床结局和联合免疫治疗反应。
Front Pharmacol. 2024 Jun 14;15:1416295. doi: 10.3389/fphar.2024.1416295. eCollection 2024.

本文引用的文献

1
Safety and clinical activity with an anti-PD-1 antibody JS001 in advanced melanoma or urologic cancer patients.抗 PD-1 抗体 JS001 治疗晚期黑色素瘤或泌尿系统癌症患者的安全性和临床活性。
J Hematol Oncol. 2019 Jan 14;12(1):7. doi: 10.1186/s13045-018-0693-2.
2
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.全球癌症统计数据 2018:GLOBOCAN 对全球 185 个国家/地区 36 种癌症的发病率和死亡率的估计。
CA Cancer J Clin. 2018 Nov;68(6):394-424. doi: 10.3322/caac.21492. Epub 2018 Sep 12.
3
Beyond microsatellite testing: assessment of tumor mutational burden identifies subsets of colorectal cancer who may respond to immune checkpoint inhibition.超越微卫星检测:肿瘤突变负荷评估可识别可能对免疫检查点抑制有反应的结直肠癌亚组。
J Gastrointest Oncol. 2018 Aug;9(4):610-617. doi: 10.21037/jgo.2018.05.06.
4
Monitoring Immune Checkpoint Regulators as Predictive Biomarkers in Hepatocellular Carcinoma.监测免疫检查点调节因子作为肝细胞癌的预测生物标志物
Front Oncol. 2018 Jul 13;8:269. doi: 10.3389/fonc.2018.00269. eCollection 2018.
5
Diverse modes of clonal evolution in HBV-related hepatocellular carcinoma revealed by single-cell genome sequencing.单细胞基因组测序揭示乙型肝炎病毒相关肝细胞癌中的多种克隆进化模式。
Cell Res. 2018 Mar;28(3):359-373. doi: 10.1038/cr.2018.11. Epub 2018 Jan 12.
6
Low Levels of Microsatellite Instability at Simple Repeated Sequences Commonly Occur in Human Hepatocellular Carcinoma.人类肝细胞癌中常见简单重复序列处微卫星不稳定性水平较低。
Cancer Genomics Proteomics. 2017 Sep-Oct;14(5):329-339. doi: 10.21873/cgp.20043.
7
Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma.肝细胞癌的综合与整合基因组特征分析
Cell. 2017 Jun 15;169(7):1327-1341.e23. doi: 10.1016/j.cell.2017.05.046.
8
Histological subtypes of hepatocellular carcinoma are related to gene mutations and molecular tumour classification.肝细胞癌的组织学亚型与基因突变和分子肿瘤分类有关。
J Hepatol. 2017 Oct;67(4):727-738. doi: 10.1016/j.jhep.2017.05.014. Epub 2017 May 19.
9
Predictive biomarkers for checkpoint inhibitor-based immunotherapy.基于检查点抑制剂的免疫疗法的预测性生物标志物。
Lancet Oncol. 2016 Dec;17(12):e542-e551. doi: 10.1016/S1470-2045(16)30406-5.
10
Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade.靶向新一代测序鉴定出对PD-1阻断治疗反应的标志物。
Cancer Immunol Res. 2016 Nov;4(11):959-967. doi: 10.1158/2326-6066.CIR-16-0143. Epub 2016 Sep 26.

中国肝细胞癌患者的突变谱及其与临床病理学的相关性

Mutation profile and its correlation with clinicopathology in Chinese hepatocellular carcinoma patients.

作者信息

Wang Shuo, Shi Huasheng, Liu Tao, Li Manjiang, Zhou Sanshun, Qiu Xuan, Wang Zusen, Hu Weiyu, Guo Weidong, Chen Xiaoqian, Guo Honglin, Shi Xiaoliang, Shi Junping, Zang Yunjin, Cao Jingyu, Wu Liqun

机构信息

Liver Disease Center, Affiliated Hospital of Qingdao University, Qingdao, China.

Department of Hepatobiliary Surgery, Affiliated Hospital of Jining Medical University, Jining, China.

出版信息

Hepatobiliary Surg Nutr. 2021 Apr;10(2):172-179. doi: 10.21037/hbsn.2019.09.17.

DOI:10.21037/hbsn.2019.09.17
PMID:33898558
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8050591/
Abstract

BACKGROUND

Hepatocellular carcinoma (HCC) is one of the most common causes of cancer worldwide. Although many studies have focused on oncogene characteristics, the genomic landscape of Chinese HCC patients has not been fully clarified.

METHODS

A total of 165 HCC patients, including 146 males and 19 females, were enrolled. The median age was 55 years (range, 27-78 years). Corresponding clinical and pathological information was collected for further analysis. A total of 168 tumor tissues from these patients were selected for next-generation sequencing (NGS)-based 450 panel gene sequencing. Genomic alterations including single nucleotide variations (SNV), short and long insertions and deletions (InDels), copy number variations, and gene rearrangements were analyzed. Tumor mutational burden (TMB) was measured by an algorithm developed in-house. The top quartile of HCC was classified as TMB high.

RESULTS

A total of 1,004 genomic alterations were detected from 258 genes in 168 HCC tissues. TMB values were identified in 160 HCC specimens, with a median TMB of 5.4 Muts/Mb (range, 0-28.4 Muts/Mb) and a 75% TMB of 7.7 Muts/Mb. The most commonly mutated genes were , and . SNV was the most common mutation type and C:G>T:A and guanine transformation were the most common SNVs. Compared to wild-type patients, the proportion of Edmondson grade III-IV and microvascular invasion was significantly higher in mutated patients (P<0.05). The proportion of tumors invading the hepatic capsule was significantly higher in mutated patients (P<0.05). The proportion of Edmondson grade I-II, alpha fetoprotein (AFP) <25 µmg/L, and those without a history of hepatitis B was significantly higher in mutated patients (P<0.05). mutations were associated with TMB high in HCC patients (P<0.05). Based on correlation analysis, the mutation of was independently correlated with microvascular invasion (P=0.002, OR =3.096) and Edmondson grade III-IV (P=0.008, OR =2.613). The mutation of was independently correlated with tumor invasion of the liver capsule (P=0.001, OR =3.030), and the mutation of was independently correlated with AFP (<25 µmg/L) (P=0.009, OR =3.414).

CONCLUSIONS

The most frequently mutated genes of HCC patients in China were , , and , which mainly lead to the occurrence and development of HCC by regulating the P53 pathway, Wnt pathway, and telomere repair pathway. There were more patients with microvascular invasion and Edmondson III-IV grade in mutated patients and more patients with hepatic capsule invasion in mutated patients, while in mutated patients, there were more patients with Edmondson I-II grade, AFP <25 µmg/L, and a non-hepatitis B background. Also, the TMB values were significantly higher in mutated patients than in wild type patients.

摘要

背景

肝细胞癌(HCC)是全球癌症最常见的病因之一。尽管许多研究聚焦于癌基因特征,但中国HCC患者的基因组格局尚未完全阐明。

方法

共纳入165例HCC患者,其中男性146例,女性19例。中位年龄为55岁(范围27 - 78岁)。收集相应的临床和病理信息用于进一步分析。从这些患者中选取168个肿瘤组织进行基于二代测序(NGS)的450基因panel测序。分析基因组改变,包括单核苷酸变异(SNV)、短插入和缺失(InDels)、拷贝数变异以及基因重排。通过内部开发的算法测量肿瘤突变负荷(TMB)。HCC的前四分位数被分类为TMB高。

结果

在168个HCC组织中的258个基因中总共检测到1004个基因组改变。在160个HCC标本中确定了TMB值,中位TMB为5.4个突变/Mb(范围0 - 28.4个突变/Mb),75%的TMB为7.7个突变/Mb。最常突变的基因是 , ,和 。SNV是最常见的突变类型,C:G>T:A和鸟嘌呤转化是最常见的SNV。与野生型患者相比, 突变患者中Edmondson III - IV级和微血管侵犯的比例显著更高(P<0.05)。 突变患者中肿瘤侵犯肝包膜的比例显著更高(P<0.05)。 突变患者中Edmondson I - II级、甲胎蛋白(AFP)<25μg/L以及无乙肝病史的患者比例显著更高(P<0.05)。 突变与HCC患者的TMB高相关(P<0.05)。基于相关性分析, 的突变与微血管侵犯独立相关(P = 0.002,OR = 3.096)和Edmondson III - IV级(P = 0.008,OR = 2.613)。 的突变与肝包膜肿瘤侵犯独立相关(P = 0.001,OR = 3.030), 的突变与AFP(<25μg/L)独立相关(P = 0.009,OR = 3.414)。

结论

中国HCC患者最常突变的基因是 , ,和 ,它们主要通过调节P53途径、Wnt途径和端粒修复途径导致HCC的发生和发展。 突变患者中微血管侵犯和Edmondson III - IV级的患者更多, 突变患者中肝包膜侵犯的患者更多,而 突变患者中Edmondson I - II级、AFP<25μg/L以及无乙肝背景的患者更多。此外, 突变患者的TMB值显著高于野生型患者。